Eight new pharmaceutical clinical trials with a value of more than $40 million are planned after the New South Wales government in Australia supported a joint venture between George Clinical and Guangzhou (China) based pharmaceutical company Link Health at the 28th biennial NSW-Guangdong Joint Economic Meeting.
Minister for Trade and Industry Stuart Ayres said George Clinical has deep experience in leveraging its scientific networks, clinical protocol design, study management, data science and global trial execution.
“Bringing together the complementary strengths of both companies will allow China and Australia to capitalize on the tremendous growth in the pharmaceutical industry in areas such as trial execution, marketing authorization and commercialization,” Mr. Ayres said. “The joint venture of Link Health and George Clinical (Link-George) will optimize the tremendous growth in pharma licensing and drug development and I congratulate them on cementing this significant new partnership.”
Link Health brings in-depth knowledge in the evaluation of pharmaceutical targets, consultation on pharmaceutical licensing and the regulatory and commercial landscape in China. Commercial Director and Country Head of George Clinical Jacqueline Thorn shared the excitement of the joint venture.
“Both parties acknowledge the help and support of the NSW and Guangdong governments, including the JEM itself, in achieving this great outcome,” Dr. Thorn said. This is a very exciting time for both George Clinical and Link Health. The formation of this joint venture has been seamless with both companies being transparent and trustful in looking for a win-win solution in China—all involved should be commended”.